Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$7.31 - $10.9 $432,766 - $645,301
59,202 New
59,202 $474,000
Q4 2023

Feb 09, 2024

BUY
$6.66 - $16.03 $434,178 - $1.05 Million
65,192 New
65,192 $728,000
Q4 2022

Feb 10, 2023

BUY
$5.52 - $12.73 $310,190 - $715,349
56,194 New
56,194 $715,000

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $415M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track Hrt Financial LP Portfolio

Follow Hrt Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Hrt Financial LP with notifications on news.